Cibus, Inc.

NASDAQ:CBUS

Biotechnology

Healthcare
$1.37 +3.10%

+$0.04 today

Market cap
$104.71M
Beta
1.65
P/E (TTM)
-8.6
EPS (TTM)
-$0.16
52W Low $1.09High $4.19

Volume 0.25M

Average 0.51M

CBUS Other Financing Activities

Financing cash flows not reported separately.

Cibus, Inc.NASDAQ: CBUS

Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026

Other financing activities declines year over year

Q1 FY2026 other financing activities of $80K (cash outflow) fell 93.2% year over year, behind the -50.6% change in trailing-twelve-month other financing activities. Sequentially, it rose 12.7% from the prior quarter. Over 3 fiscal years it compounded at -50.5% a year.

Context

  • Other financing activities amounted to 3.9% of revenue in FY2025, down 53.0 pp from a year earlier.
  • Other financing activities increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -93.2% toward the trailing-twelve-month pace of -50.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$80K+12.7% QoQ
Last fiscal yearDec 2025
-$142K-94.1% YoY
LTMMar 2026
-$991K-50.6% YoY
Other Financing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-93.2%——
1 year-94.1%——
3-year CAGR-50.5%——
5-year CAGR——
10-year CAGR——

Other Financing Activities history

USD · from the cash flow

Latest · FY2025
(142K) USD
Year-over-year change
+94.1%

Other Financing Activities vs competitors

How CBUS compares with its peers on the latest reported figures

  • CBUS's LTM Mar 2026 other financing activities of $991K is the 2nd largest of the 10 companies compared; the peer median is $0.
  • Its year-over-year change of -50.6% is the 4th highest of 9, against a peer median of -81.5%.
  • Other financing activities amounts to 23.1% of revenue for CBUS, versus a peer median of 40.9%.
CBUS Competitors Peer median
Other Financing Activities for CBUS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$14.95M -79.3%—380.0%
CBUSCibus, Inc.LTM Mar 2026$991K -50.6%-50.5%23.1%
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$923K +435.6%+49.5%—
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$439K -83.7%-35.1%—
VXRTVaxart, Inc.LTM Mar 2026$291K -329.1%—0.1%
MNOVMediciNova, Inc.LTM Mar 2026$244.02K ——40.9%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$138.67K -47.1%——
BMEABiomea Fusion, Inc.LTM Mar 2026$3K -100.2%——
IMUXImmunic, Inc.LTM Mar 2026$1 +100.0%——
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$0 -100.0%——
Peer median (excluding CBUS) $0-81.5%+7.2%40.9%

Competitors are the stored peer set for CBUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(29.2M)(16.89M)(267.63M)(282.71M)(127.09M)
Depreciation & Amortization2.34M1.53M4.69M6.86M5.92M
Deferred Income Tax00000
Stock-Based Compensation2.09M4M16.09M10.75M8.19M
Change in Working Capital7.49M(2.89M)961K383K2.32M
Accounts Receivables4.89M01.7M(512K)538K
Inventory1.38M0000
Accounts Payables(360K)(229K)2K(188K)720K
Other Working Capital1.58M(2.66M)(745K)1.08M1.06M
Other Non-Cash Items(1.53M)(5.12M)215.76M206.68M60.06M
Operating Cash Flow(18.81M)(19.36M)(46.21M)(58.04M)(50.59M)
Capital Expenditures(497K)(1.52M)(4.32M)(808K)(578K)
Acquisitions (Net)0059.38M00
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities11.7M0000
Investing Cash Flow11.2M(1.52M)55.06M(808K)(578K)
Debt Repayment(364K)(376K)(194K)(879K)(1.11M)
Common Stock Issued4.38M11.54M18.76M43.9M47.9M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(274K)(1.17M)1.76M(2.43M)(142K)
Financing Cash Flow3.74M9.99M20.32M40.6M46.65M
Effect of Forex Changes498K99K3K(13K)11K
Net Change in Cash(3.87M)(10.9M)29.17M(18.27M)(4.51M)
Free Cash Flow(19.31M)(20.88M)(50.53M)(58.85M)(51.17M)

Cibus, Inc.

NASDAQ:CBUS

Intrinsic Alpha fair value

Locked

Current Price

$1.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.